People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday.  The ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...